MedPath

Fluzoparib

Generic Name
Fluzoparib
Drug Type
Small Molecule
Chemical Formula
C22H16F4N6O2
CAS Number
1358715-18-0
Unique Ingredient Identifier
TWF0ML1CK8
Background

Fluzoparib is under investigation in clinical trial NCT03863860 (A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients).

Indication

⑴适用于既往经过二线及以上化疗的伴有胚系BRCA突变(gBRCAm)的铂敏感复发性卵巢癌、输卵管癌或原发性腹膜癌患者的治疗。⑵适用于铂敏感的复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌成人患者在含铂化疗达到完全缓解或部分缓解后的维持治疗。

Clinical Trials
Related News

A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Phase 3
Recruiting
Conditions
Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
Interventions
Drug: Physician's choice chemotherapy
First Posted Date
2020-03-05
Last Posted Date
2020-08-10
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
474
Registration Number
NCT04296370
Locations
🇨🇳

Jiangsu HengRui Medicine Co., Ltd., Shanghai, China

A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy

Phase 3
Conditions
Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Carcinoma
Interventions
Drug: Placebo
First Posted Date
2020-01-18
Last Posted Date
2022-04-25
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
690
Registration Number
NCT04229615
Locations
🇨🇳

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer

Phase 1
Completed
Conditions
Advanced Pancreatic Cancer
Interventions
Drug: mFOLFIRINOX
First Posted Date
2020-01-14
Last Posted Date
2024-08-16
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
39
Registration Number
NCT04228601
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

🇨🇳

Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China

Effect of Fluconazole on PK of Fluzoparib in Healthy Male Subjects

Phase 1
Completed
Conditions
Advanced Cancer
Interventions
First Posted Date
2019-12-10
Last Posted Date
2019-12-10
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
20
Registration Number
NCT04193319
Locations
🇨🇳

Early Cancer Research Center of Hunan Cancer Hospital, Hunan, Hunan, China

Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects

Phase 1
Completed
Conditions
Advanced Solid Tumor
Interventions
First Posted Date
2019-09-30
Last Posted Date
2022-07-29
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
16
Registration Number
NCT04108676
Locations
🇨🇳

The third xiangya hospital Hospital,of central south university, Changsha, Hunan, China

A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC

Phase 2
Conditions
Prostate Cancer
Castration-resistant Prostate Cancer
Interventions
Drug: SHR3680(Placebo)
Drug: SHR3162(Placebo)
First Posted Date
2019-09-25
Last Posted Date
2020-05-14
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
144
Registration Number
NCT04102124
Locations
🇨🇳

Ye Dingwei, Shanghai, China

A Drug-drug Interaction Trial of Rifampicin Pharmacokinetics Effect on Fluzoparib

Phase 1
Completed
Conditions
Healthy Male Subjects
Interventions
First Posted Date
2019-07-08
Last Posted Date
2020-02-26
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
16
Registration Number
NCT04011124
Locations
🇨🇳

First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients

Phase 3
Conditions
Ovarian Cancer
Interventions
Drug: Placebo capsules
First Posted Date
2019-03-05
Last Posted Date
2022-06-13
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
252
Registration Number
NCT03863860
Locations
🇨🇳

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

Treatment of Carrying TP53 Harmful Mutations

Phase 1
Conditions
Advanced Cancer
Interventions
First Posted Date
2018-08-24
Last Posted Date
2019-04-25
Lead Sponsor
Tianjin Medical University Second Hospital
Target Recruit Count
60
Registration Number
NCT03645200
Locations
🇨🇳

Tianjin Medical Unversity Second Hospital, Tianjin, Tianjin, China

A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer

Phase 1
Completed
Conditions
Ovarian Cancer
Interventions
First Posted Date
2018-04-26
Last Posted Date
2022-07-01
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
113
Registration Number
NCT03509636
Locations
🇨🇳

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy